Mavefund EN
4D Molecular Therapeutics Inc logo

4D Molecular Therapeutics Inc

FDMT
Letzter Kurs (USD) US$13.98
Marktkapitalisierung (USD) US$762.1m
Kursänderung 12 Monate 126.95%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
Halozyme Therapeutics IncHALO Vergleich Corcept Therapeutics IncorporatedCORT Vergleich Exelixis IncEXEL Vergleich Zoetis IncZTS Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

4D Molecular Therapeutics Inc Überblick

Branche: Biotechnology

Sektor: Healthcare

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California. 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The co

Research-Überblick

Letztes Berichtsdatum 2026-08-13

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu 4D Molecular Therapeutics Inc (FDMT): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
FDMT · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Biotechnology
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-13
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von 4D Molecular Therapeutics Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 13, 2026

Quarterly result summary

Revenue was $3.8M (reported). Net loss was -$72.9M (from $54.7M). R&D expense was $68.3M.

Revenue $3.8M reported
Net loss -$72.9M from $54.7M
R&D expense $68.3M reported
G&A expense $12.5M reported

Was sich verändert hat

  • Revenue reported to $3.8M.
  • Net loss was -$72.9M (from $54.7M).

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing 8-K Aug 13, 2026 SEC filing 10-Q Aug 13, 2026 SEC filing 10-Q May 07, 2026 SEC filing 8-K May 07, 2026 Earnings release Earnings release May 07, 2026 SEC filing 8-K Mar 18, 2026 Earnings release Earnings release Mar 18, 2026 SEC filing 10-K Mar 18, 2026 SEC filing 8-K Jan 07, 2026 SEC filing 10-Q Nov 10, 2025 SEC filing 8-K Nov 10, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 3.00/5
4D Molecular Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Eigenkapitalrendite

Score 1.52/5
4D Molecular Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
4D Molecular... FDMT US$762.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 0.85/5
4D Molecular Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
4D Molecular... FDMT US$762.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Verschuldung

Score 3.85/5
4D Molecular Therapeutics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
4D Molecular... FDMT US$762.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

4D Molecular Therapeutics Inc logo

4D Molecular Therapeutics Inc

US$13.98

US$762.1m

-9.10%

126.95%